Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions

Dr.Reddy's Laboratories

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Anastrozole

Study type

Interventional

Funder types

Industry

Identifiers

NCT01155960

BA0859094

Details and patient eligibility

About

The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fed conditions.

Full description

Open label, balanced, randomized, two treatment, two-sequence, two periods, crossover, single dose, comparative oral bioavailability study in healthy, post menopausal women subjects under fed conditions.

Enrollment

36 patients

Sex

Female

Ages

37 to 67 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

The subjects should be postmenopausal healthy women who have attained complete menopause naturally or surgically and have not had menstruation for at least one year and are not on hormone replacement therapy.
The subjects should have Estradiol level ≤ 20 pg/ml & serum follicular stimulating hormone (FSH) level ≥ 50 mlU/ml during the screening.
The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
The subjects should have a BMI between 18.5 to 26.4 (30-39 years), 18.5 to 27.8 (40-49 years), 18.5 to 28.4 (50-59 years) & 18.5 to 27.5 (60-69 years) weight in kg/ height2 in meter.
The subjects should be able to communicate effectively with study personnel.
The subjects should be able to give written informed consent to participate in the study.

Exclusion criteria

The subjects who have a history of allergic responses to Anastrozole or other related drugs.
The subjects who are using female hormone replacement therapies, thyroid hormone replacement therapies, or antihypertensive therapies.
The subjects who have significant diseases or clinically significant abnormal findings during screening, (medical history, physical examination, laboratory evaluations, ECG, X-ray & lower abdominal ultrasonography recordings).
The subjects who have any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
The subjects who have a history or presence of bronchial asthma.
The subject who have used of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
The subjects who have history of drug dependence, recent history of alcoholism or of moderate alcohol use.
The subjects who are smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who cannot refrain from smoking during study period.
The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
The subjects who have donated (1 unit: 350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
The subjects who have a positive test result for Human Immunodeficiency Virus (HIV) antibody and / or syphilis Rapid Plasma Reagin, Venereal Disease Research Laboratory (RPR/VDRL).
The subject who received an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.